Osteonecrosis of the jaws: Clinicopathologic and radiologic characteristics, preventive and therapeutic strategies

Strahlentherapie und Onkologie

Volumn 186, Issue 7, 2010, Pages 367-373

  Vassiliou, Vassilios ^a   Tselis, Nikolaos ^b   Kardamakis, Dimitrios ^c  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b Klinikum Offenbach   (Germany)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bisphosphonates; Imaging; Osteonecrosis of the jaws; Radiotherapy; Surgery

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; HEMOGLOBIN; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGE; ALCOHOL CONSUMPTION; BLOOD CLOTTING DISORDER; BONE NECROSIS; BONE SCINTISCANNING; CHEMOTHERAPY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DENTAL RADIOLOGY; DENTAL SURGERY; DENTURE; DISEASE CLASSIFICATION; DRUG EXPOSURE; DRUG POTENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOCOMPROMISED PATIENT; JAW OSTEONECROSIS; LOCAL METASTASIS; MOUTH HYGIENE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DYSESTHESIA; PAIN; PANORAMIC RADIOGRAPHY; PARESTHESIA; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; PERIODONTAL EXAMINATION; PREVENTION AND CONTROL; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SOFT TISSUE INFLAMMATION; STRUCTURE ACTIVITY RELATION; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DIAGNOSTIC IMAGING; DISEASE COURSE; INTERDISCIPLINARY COMMUNICATION; INTRAVENOUS DRUG ADMINISTRATION; MANDIBLE; MAXILLA; METASTASIS; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT CARE; PROGNOSIS; RISK FACTOR;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DIPHOSPHONATES; DISEASE PROGRESSION; HUMANS; INFUSIONS, INTRAVENOUS; INTERDISCIPLINARY COMMUNICATION; MANDIBLE; MAXILLA; OSTEONECROSIS; PATIENT CARE TEAM; PROGNOSIS; RISK FACTORS;

EID: 77954907457     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2066-9     Document Type: Review

References (60)

1. M. Aapro P.A. Abrahamsson J.J. Body 2008 Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel Ann Oncol 19 420 32 10.1093/annonc/mdm442 1:STN:280:DC%2BD1c7ksVSrug%3D%3D
2. I.A. Adamietz 1997 The efficacy of pamidronate in reducing skeletal associated events in patients with advanced multiple myeloma Strahlenther Onkol 173 52 3 10.1007/BF03039196 1:STN:280:DyaK2s3hs1eguw%3D%3D
3. I.A. Adamietz 1998 Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomised, controlled multinational study Strahlenther Onkol 174 438 10.1007/BF03038568 1:STN:280:DyaK1cvhtFOjtg%3D%3D
4. M.C. Adornato I. Morcos J. Rozanski 2007 The treatment of bisphosphonateassociated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors J Am Dent Assoc 138 971 7
5. A. Bamias E. Kastritis C. Bamia 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 7 10.1200/JCO.2005.02.8670 (Pubitemid 46211499)
6. S.D. Bianchi M. Scoletta F.B. Cassione 2007 Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 249 58 10.1016/j.tripleo.2007.01.040
7. J.J. Body I.J. Diel R. Bell 2004 Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer Pain 111 306 12 10.1016/j.pain.2004.07.011 1:CAS:528:DC%2BD2cXnsFSqs7c%3D (Pubitemid 39201152)
8. J.J. Body I.J. Diel M.R. Lichinitser 2003 Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 1399 405 10.1093/annonc/mdg367 (Pubitemid 37185286)
9. J.J. Body I.J. Diel M.R. Lichinitser 2004 Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies Br J Cancer 90 1133 7 10.1038/sj.bjc.6601663 1:CAS:528:DC%2BD2cXitV2rs7w%3D (Pubitemid 38496803)
10. E. Bölke P.A. Gerber G. Lammering 2008 Development and management of severe cutaneous side effects in head-and-neck cancer during concurrent radiotherapy and cetuximab Strahlenther Onkol 184 105 10 10.1007/s00066-008- 1829-z (Pubitemid 351231657)
11. D. Bottke K. Bathe T. Wiegel 2007 Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck Strahlenther Onkol 183 128 32 10.1007/s00066-007-1597-1 (Pubitemid 46364895)
12. J.E. Brown H. Neville-Webbe R.E. Coleman 2004 The role of bisphosphonates in breast and prostate cancers Endocr Relat Cancer 11 207 24 10.1677/erc.0.0110207 1:CAS:528:DC%2BD2cXlsl2msLk%3D (Pubitemid 38832826)
13. S. Chiandussi M. Biasotto F. Dore 2006 Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws Dentomaxillofac Radiol 35 236 43 10.1259/dmfr/27458726 1:STN:280:DC%2BD28zotFSkuw%3D%3D (Pubitemid 44076879)
14. R.E. Coleman 2004 Bisphosphonates: clinical experience Oncologist 9 14 27 10.1634/theoncologist.9-90004-14 1:CAS:528:DC%2BD2cXpslGhtbs%3D (Pubitemid 39363165)
15. M.M. Curi G.S. Cossolin D.H. Koga 2007 Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases J Oral Maxillofac Surg 65 349 55 10.1016/j.joms.2005. 12.051 (Pubitemid 46131421)
16. Damato K, Gralow J, Hoff A, et al. Expert panel recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaws. Dockets management, US Food and Drug Administration (available at http://www. fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2-02-12-Novartis-Zometa-App-11. pdf, accessed October 25, 2007).
17. I.J. Diel 2007 Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review Support Care Cancer 15 1243 9 10.1007/s00520-007-0244-9 (Pubitemid 47583446)
18. I.J. Diel J.J. Body M.R. Lichinitser 2004 Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer Eur J Cancer 40 1704 12 10.1016/j.ejca.2004.03.025 1:CAS:528:DC%2BD2cXls1Wntrw%3D (Pubitemid 38902906)
19. J.E. Dunford K. Thompson F.P. Coxon 2001 Structure-activity relationships for inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 296 235 42 1:CAS:528:DC%2BD3MXoslaluw%3D%3D
20. B.G. Durie M. Katz J. McCoy 2005 Osteonecrosis of the jaws in myeloma: analysis of risk factors including time dependency of Aredia and Zometa use, steroid use and underlying dental problems Haematologica 90 190a
21. H. Fleisch 2002 Development of bisphosphonates Breast Cancer Res 4 30 4 10.1186/bcr414 1:CAS:528:DC%2BD38XhsFaisLs%3D (Pubitemid 34097554)
22. J.J. Freiberger R. Padilla-Burgos A.H. Chhoeu 2007 Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series J Oral Maxillofac Surg 65 1321 7 10.1016/j.joms.2007.03.019 (Pubitemid 46907400)
23. J.B. Gibbs A. Oliff 1997 The potential of farnesyltransferase inhibitors as cancer chemotherapeutics Annu Rev Pharmacol Toxicol 37 143 66 10.1146/annurev.pharmtox.37.1.143 1:CAS:528:DyaK2sXisl2ksLc%3D
24. J. Gralow D.J. Tripathy 2007 Managing metastatic bone pain: the role of bisphosphonates J Pain Symptom Manage 33 462 472 10.1016/j.jpainsymman.2007.01. 001 1:CAS:528:DC%2BD2sXltFOju7c%3D (Pubitemid 46482947)
25. J.R. Green K. Müller K.A.J. Jaeggi 1994 Preclinical pharmacology of CGP 42†446, a new, potent, heterocyclic bisphosphonate compound Bone Miner Res 9 745 51 10.1002/jbmr.5650090521 1:CAS:528:DyaK2cXlt1Gitro%3D
26. K.A. Grötz C. Walter C. Küttner 2007 Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases Strahlenther Onkol 183 190 4 10.1007/s00066-007-1666-5 (Pubitemid 46570761)
27. R. Gutta P.J. Louis 2007 Bisphosphonates and osteonecrosis of the jaws: science and rationale Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 186 93 10.1016/j.tripleo.2006.12.004
28. D. Heyman B. Ory F. Gouin 2004 Bisphosphonates: new therapeutic agents for the treatment of bone tumors Trends Mol Med 10 337 43 10.1016/j.molmed.2004. 05.007 (Pubitemid 38881523)
29. P.J. Hoskin 2003 Bisphosphonates and radiation therapy for palliation of metastatic bone disease Cancer Treat Rev 29 321 7 10.1016/S0305-7372(03)00013-6 1:CAS:528:DC%2BD3sXmsVCnsL4%3D (Pubitemid 37069662)
30. R. Krempien A. Niethammer W. Harms J. Debus 2005 Bisphosphonates and bone metastases: current status and future directions Expert Rev Anticancer Ther 5 295 305 10.1586/14737140.5.2.295 1:CAS:528:DC%2BD2MXktlajtrc%3D
31. R. Landesberg M. Cozin S. Cremers 2008 Inhibition of oral mucosal cell wound healing by bisphosphonates J Oral Maxillofac Surg 66 839 47 10.1016/j.joms.2008.01.026 (Pubitemid 351522817)
32. R.E. Marx Y. Sawatari M. Fortin V. Broumand 2005 Bisphosphonate-induced exposed bone osteonecrosis/osteopetrosis of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 1567 75 10.1016/j.joms.2005.07.010 (Pubitemid 41525412)
33. P. Masarachia M. Weinreb R. Balena 1996 Comparison of the distribution of 3H-aledronate and 3H-etidronate in rat and mouse bones Bone 19 281 90 10.1016/8756-3282(96)00182-2 1:CAS:528:DyaK28XlvFehtb0%3D (Pubitemid 26305769)
34. B. Methora S. Ruggiero 2006 Bisphosphonates complications including osteonecrosis of the jaw Hematology Am Soc Hematol Educ Program 525 356 60
35. Migliorati CA. Bisphosphonates in the treatment of bone metastases - osteonecrosis of the jaw. In: Kardamakis D, Vassiliou V, Chow E, eds. Cancer Metastasis - Biology and Treatment, Vol 12: Bone metastases: a translational and clinical approach, Springer Netherlands, 2009:251-62.
36. M.S. Moreira E. Katayama A.C. Bombana M.M. Marques 2005 Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study Dent Traumatol 21 329 35 10.1111/j.1600-9657.2005.00370.x 1:CAS:528:DC%2BD28XitFGquw%3D%3D (Pubitemid 41687773)
37. A. Olthoff A. Ewen H.A. Wolff 2009 Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer Strahlenther Onkol 185 303 9 10.1007/s00066-009-1967-y
38. S.M. Ott 2005 Long-term safety of bisphosphonates J Clin Endocrinol Metab 90 1897 9 10.1210/jc.2005-0057 1:CAS:528:DC%2BD2MXisVOhu7w%3D (Pubitemid 40464065)
39. Pavlakis N, Stocker M. Bisphosphonates for breast cancer. The Cochrane Library, issue 1. Oxford: Update Software, 2002.
40. M.N. Polizzotto V. Cousins A.P. Schwarer 2006 Bisphosphonate-associated osteonecrosis of the auditory canal Br J Haematol 132 114 10.1111/j.1365-2141. 2005.05833.x (Pubitemid 43381578)
41. C.C. Quattrocchi D. Santini P. Dell'Aia 2007 A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid Skeletal Radiol 36 1121 7 10.1007/s00256-007-0388-1 (Pubitemid 350112381)
42. D. Rades M. Stoehr T. Meyners 2008 Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer Strahlenther Onkol 184 198 205 10.1007/s00066-008-1825-3 (Pubitemid 351508132)
43. I.R. Reid M.J. Bolland A.B. Grey 2007 Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 318 20 10.1016/j.bone.2007.04.196 1:CAS:528:DC%2BD2sXovFOqsb8%3D (Pubitemid 47199147)
44. M.J. Rogers R.J. Brown V. Hodkin 1996 Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes Biochem Biophys Res Commun 224 863 9 10.1006/bbrc.1996.1113 1:CAS:528:DyaK28Xks1Wju70%3D (Pubitemid 26278675)
45. M.J. Rogers S. Gordon H.L. Benford 2000 Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 2961 78 10.1002/1097-0142(20000615)88: 12+<2961:AID-CNCR12>3.0.CO;2-L 1:CAS:528:DC%2BD3cXksVCmsLw%3D
46. L. Rosen D. Gordon S. Tchekmedyian 2003 Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 3150 7 10.1200/JCO.2003.04.105 1:CAS:528:DC%2BD2cXpsVWqtb0%3D (Pubitemid 46606297)
47. M. Sato W. Grasser N. Endo 1991 Bisphosphonate action. Aledronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 2095 105 10.1172/JCI115539 1:CAS:528:DyaK38XjsVGgtA%3D%3D
48. N. Sauer D. Leising B. Wild 2006 Der Einfluss palliativer Strahlentherapie auf Schmerz und Lebensqualität bei Patienten mit Knochenmetastasen Strahlenther Onkol 182 550 6 10.1007/s00066-006-1510-3 (Pubitemid 44316245)
49. H.C. Schwartz 1982 Osteonecrosis of the jaws: a complication of cancer chemotherapy Head Neck Surg 4 251 3 10.1002/hed.2890040313 1:STN:280: DyaL387ms1yiug%3D%3D
50. D. Steinmann C. Schäfer B. van Oorschot 2009 Effects of radiotherapy for brain metastases on quality of life (QoL). Prospective pilot study of the DEGRO QoL Working Party Strahlenther Onkol 185 190 7 10.1007/s00066-009-1904-0
51. T. Storm T. Steiniche G. Thamsborg F. Melsen 1993 Changes in bone histomorphometry after long term treatment with intermittent, cyclic etidronate for post menopausal osteoporosis J Bone Miner Res 8 199 208 10.1002/jbmr. 5650080211 1:STN:280:DyaK3s7ot1Khuw%3D%3D
52. G. Studer K.W. Gratz C. Glanzmann 2004 Osteoradionecrosis of the mandibula in patients treated with different fractionations Strahlenther Onkol 180 233 40 10.1007/s00066-004-1171-z (Pubitemid 38461548)
53. G. Studer S.P. Studer R.A. Zwahlen 2006 Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT) Strahlenther Onkol 182 283 8 10.1007/s00066-006-1477-0
54. V. Vassiliou C. Kalogeropoulou C. Christopoulos 2007 Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment Int J Radiat Oncol Biol Phys 67 264 72 1:CAS:528:DC%2BD2sXpslej
55. V. Vassiliou D. Kardamakis 2009 The management of metastatic bone disease with combination of bisphosphonates and radiotherapy: from theory to clinical practice Anticancer Agents Med Chem 9 323 35
56. P. Vescovi E. Merigo M. Manfredi 2008 Nd:Yag laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases Photomed Laser Surg 26 37 46 10.1089/pho.2007.2181 (Pubitemid 351206155)
57. D. Vomvas V. Vassiliou D. Papavasileiou 2008 Osteonecrosis of the jaw in a patient treated with ibandronate J BUON 13 441 2 1:STN:280: DC%2BD1cjht1aqtQ%3D%3D
58. R. Weitzman N. Sauter E.F. Eriksen 2007 Critical review: Updated recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw in cancer patients Crit Rev Oncol Hematol 62 148 52 10.1016/j. critrevonc.2006.12.005 (Pubitemid 46575276)
59. S.B. Woo J.W. Hellstein J.R. Kalmar 2006 Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 753 61 1:CAS:528:DC%2BD28XlsFKhs70%3D
60. T.V. Wyngear M.T. Huizing J.D. Vermoken 2007 Osteonecrosis of the jaw related to the use of bisphosphonates Curr Opin Oncol 19 315 22 10.1097/CCO.0b013e32819f820b (Pubitemid 46883519)